Article | March 3, 2017

Modeling And Simulation In Clinical Trials: Real Potential Or Hype?

Modeling And Simulation In Clinical Trials: Real Potential Or Hype?

By Craig Morgan, goBalto

Improving experimental drug success rate1 and accelerating clinical developmentare top priorities for pharmaceutical companies. Careful decision making during drug development is essential to minimize development time, manage costs and improve the probability of commercial success. Recently, many of the major pharmaceutical companies have begun to explore computer-based bio-simulation strategies to help generate the information necessary to make better decisions.3,4 These strategies go by many different names – clinical trial simulation (CTS), modeling and simulation (M&S), computer-assisted trial design (CATD), model-based drug development (MBDD), and model-informed drug discovery and development (MID3). The FDA and EMA regulatory agencies have also taken notice of M&S strategies in an effort to support improved drug development efficiencies.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: